Yozu et al. [5] described a patient with MTS and pleomorphic liposarcoma presenting loss of MSH2/MSH6 expression and a confirmed MSH2 germline pathogenic variant. This evidence concerns the gene MSH2 and pleomorphic liposarcoma.